Dova Pharmaceuticals, Inc. (NASDAQ:DOVA) – Research analysts at Jefferies Group issued their Q1 2018 EPS estimates for Dova Pharmaceuticals in a research note issued to investors on Thursday. Jefferies Group analyst E. Yang forecasts that the company will earn ($0.42) per share for the quarter. Jefferies Group currently has a “Buy” rating and a $30.00 target price on the stock. Jefferies Group also issued estimates for Dova Pharmaceuticals’ Q2 2018 earnings at ($0.45) EPS, Q3 2018 earnings at ($0.46) EPS and Q4 2018 earnings at ($0.53) EPS.
Dova Pharmaceuticals (NASDAQ:DOVA) last released its quarterly earnings data on Thursday, November 9th. The company reported ($0.38) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.30) by ($0.08). During the same quarter in the prior year, the business posted ($0.41) EPS.
Other analysts also recently issued research reports about the stock. J P Morgan Chase & Co assumed coverage on shares of Dova Pharmaceuticals in a report on Monday, July 24th. They issued an “overweight” rating and a $35.00 price objective for the company. Leerink Swann upgraded shares of Dova Pharmaceuticals from a “market perform” rating to an “outperform” rating and set a $32.00 price objective for the company in a report on Tuesday, September 26th. Finally, Zacks Investment Research upgraded shares of Dova Pharmaceuticals from a “hold” rating to a “buy” rating and set a $31.00 price objective for the company in a report on Wednesday, October 11th.
Shares of Dova Pharmaceuticals (NASDAQ DOVA) opened at $23.13 on Monday. Dova Pharmaceuticals has a 1-year low of $16.98 and a 1-year high of $29.99.
In other news, Director Paul B. Manning purchased 25,870 shares of the business’s stock in a transaction dated Wednesday, August 16th. The stock was acquired at an average price of $22.30 per share, for a total transaction of $576,901.00. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, Director Steven M. Goldman purchased 20,169 shares of the business’s stock in a transaction dated Tuesday, August 15th. The shares were purchased at an average price of $22.23 per share, with a total value of $448,356.87. Following the acquisition, the director now directly owns 81,158 shares in the company, valued at $1,804,142.34. The disclosure for this purchase can be found here.
Hedge funds and other institutional investors have recently made changes to their positions in the company. Laurion Capital Management LP acquired a new stake in shares of Dova Pharmaceuticals during the 2nd quarter worth approximately $223,000. Bank of New York Mellon Corp acquired a new stake in shares of Dova Pharmaceuticals during the 3rd quarter worth approximately $340,000. JPMorgan Chase & Co. acquired a new stake in shares of Dova Pharmaceuticals during the 2nd quarter worth approximately $382,000. Vanguard Group Inc. acquired a new stake in shares of Dova Pharmaceuticals during the 2nd quarter worth approximately $390,000. Finally, Goldman Sachs Group Inc. acquired a new stake in shares of Dova Pharmaceuticals during the 2nd quarter worth approximately $493,000. Institutional investors and hedge funds own 23.67% of the company’s stock.
About Dova Pharmaceuticals
Dova Pharmaceuticals, Inc is a clinical-stage pharmaceutical company. The Company is focused on acquiring, developing and commercializing drug candidates. The Company’s initial focus is on thrombocytopenia, a disorder characterized by a low blood platelet count. The Company is developing avatrombopag for treatment of thrombocytopenia in patients with chronic liver disease (CLD).
Receive News & Ratings for Dova Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dova Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.